Related Experiment Videos
The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
1Department of Pathology and Laboratory Medicine, Albany Medical College, 47 New Scotland Avenue, Albany, MA, NY 12208, USA.
Seminars in Cancer Biology
|April 15, 1999
Summary
HER-2/neu receptor tyrosine kinase status impacts breast cancer outcomes. This review explores its role in predicting treatment response and potential as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor.
- HER-2/neu shares homology with the epidermal growth factor receptor.
- HER-2/neu is extensively studied in the context of breast cancer.
Purpose of the Study:
- To review the prognostic and predictive value of HER-2/neu status in breast cancer.
- To evaluate the impact of HER-2/neu status on patient outcomes across different therapies.
- To discuss novel therapeutic strategies targeting HER-2/neu.
Main Methods:
- Literature review of recently published studies.
- Analysis of HER-2/neu status in relation to treatment response (hormonal, cytotoxic, radiation).
- Examination of serum-based HER-2/neu testing and antibody-based therapies.
Main Results:
- HER-2/neu status demonstrates a variable impact on patient outcomes with established breast cancer therapies.
- Serum-based testing offers a potential non-invasive method for monitoring HER-2/neu.
- Antibody-based therapies targeting HER-2/neu show promise for breast cancer treatment.
Conclusions:
- HER-2/neu status is a significant factor in breast cancer prognosis and predicting treatment efficacy.
- Targeting HER-2/neu with therapies like antibodies represents a developing modality for breast cancer management.